Revealed the mechanism of action of solnatide, a possible treatment for pulmonary edema

Solnatide is a synthetic peptide, which is in clinical trials to treat (life-threatening) lung failure in patients with Acute Respiratory Distress Syndrome (ARDS) and COVID-19.

In this project, the researchers detail the structure of solnatide and propose a mechanism of interaction with the ENaC sodium channel of cells, which is related to the volume of liquid in the cellular environment.

The work has been published in the Computational and Structural Biotechnology Journal.

Pulmonary edema is an abnormal accumulation of fluid in the lungs that results in shortness of breath, is life-threatening, and occurs in patients with acute respiratory distress syndrome and COVID-19. This accumulation of fluid causes a lack of oxygenation of the blood and is related to defects in the functioning of the sodium channels responsible for regulating water levels inside and outside the cells.

A collaboration led by Dr. Maria Macias, ICREA researcher and head of the Structural Characterization of Macromolecular Assemblies laboratory at IRB Barcelona, ​​and Dr. Susan Tzotzos, from the Austrian biotech APEPTICO, has revealed the structure of solnatide, a molecule that is being being tested for the treatment of pulmonary edema. Specifically, this project has made it possible to detail the mechanism of interaction of sonatide with the ENaC sodium channel of the cell, responsible for the elimination of pulmonary fluid.

The APEPTICO company from Vienna (Austria), owner of solnatide, has been working with this molecule for many years, studying its biological function. At the moment, the molecule is in the clinical trial phase to treat pulmonary edema in patients with Acute Respiratory Distress Syndrome (ARDS), as well as severe COVID-19 patients with ARDS.

"Our work has focused on describing the structure of the peptide and proposing a mechanism of action to open the door to possible improvements in its sequence, that is, to small modifications that can make it more effective," explains Dr. Macías.

A helix and a dipole

The structure of the sodium channel in cells was already partially described, but there remained a less structured region that was not yet known. In this work, published in the Computational and Structural Biotechnology Journal, the researchers have used structure prediction tools including Alphafold, to identify a helical region aligned with the cell membrane, by the cytoplasmic part. That helix would have a positively charged region and a negatively charged region.

The solnatide, for its part, also had a region called a "dipole", with a negative and a positive charge. Thus, the researchers were able to predict that this would be the point of interaction between both structures and how they were positioned for that interaction.

Researchers from the Catalan biotech BCN Peptides in Barcelona (Spain), and from the American universities Medical College of Georgia at Augusta University and Emory University School of Medicine, in Atlanta, have also collaborated in the work.

Pulmonary edema is an abnormal accumulation of fluid in the lungs that results in shortness of breath, is life-threatening, and occurs in patients with acute respiratory distress syndrome and COVID-19. This accumulation of fluid causes a lack of oxygenation of the blood and is related to defects in the functioning of the sodium channels responsible for regulating water levels inside and outside the cells.

A collaboration led by Dr. Maria Macias, ICREA researcher and head of the Structural Characterization of Macromolecular Assemblies laboratory at IRB Barcelona, ​​and Dr. Susan Tzotzos, from the Austrian biotech APEPTICO, has revealed the structure of solnatide, a molecule that is being being tested for the treatment of pulmonary edema. Specifically, this project has made it possible to detail the mechanism of interaction of sonatide with the ENaC sodium channel of the cell, responsible for the elimination of pulmonary fluid.

The APEPTICO company from Vienna (Austria), owner of solnatide, has been working with this molecule for many years, studying its biological function. At the moment, the molecule is in the clinical trial phase to treat pulmonary edema in patients with Acute Respiratory Distress Syndrome (ARDS), as well as severe COVID-19 patients with ARDS.

"Our work has focused on describing the structure of the peptide and proposing a mechanism of action to open the door to possible improvements in its sequence, that is, to small modifications that can make it more effective," explains Dr. Macías.

A helix and a dipole

The structure of the sodium channel in cells was already partially described, but there remained a less structured region that was not yet known. In this work, published in the Computational and Structural Biotechnology Journal, the researchers have used structure prediction tools including Alphafold, to identify a helical region aligned with the cell membrane, by the cytoplasmic part. That helix would have a positively charged region and a negatively charged region.

The solnatide, for its part, also had a region called a "dipole", with a negative and a positive charge. Thus, the researchers were able to predict that this would be the point of interaction between both structures and how they were positioned for that interaction.

Researchers from the Catalan biotech BCN Peptides in Barcelona (Spain), and from the American universities Medical College of Georgia at Augusta University and Emory University School of Medicine, in Atlanta, have also collaborated in the work.

Pulmonary edema is an abnormal accumulation of fluid in the lungs that results in shortness of breath, is life-threatening, and occurs in patients with acute respiratory distress syndrome and COVID-19. This accumulation of fluid causes a lack of oxygenation of the blood and is related to defects in the functioning of the sodium channels responsible for regulating water levels inside and outside the cells.

A collaboration led by Dr. Maria Macias, ICREA researcher and head of the Structural Characterization of Macromolecular Assemblies laboratory at IRB Barcelona, ​​and Dr. Susan Tzotzos, from the Austrian biotech APEPTICO, has revealed the structure of solnatide, a molecule that is being being tested for the treatment of pulmonary edema. Specifically, this project has made it possible to detail the mechanism of interaction of sonatide with the ENaC sodium channel of the cell, responsible for the elimination of pulmonary fluid.

The APEPTICO company from Vienna (Austria), owner of solnatide, has been working with this molecule for many years, studying its biological function. At the moment, the molecule is in the clinical trial phase to treat pulmonary edema in patients with Acute Respiratory Distress Syndrome (ARDS), as well as severe COVID-19 patients with ARDS.

"Our work has focused on describing the structure of the peptide and proposing a mechanism of action to open the door to possible improvements in its sequence, that is, to small modifications that can make it more effective," explains Dr. Macías.

A helix and a dipole

The structure of the sodium channel in cells was already partially described, but there remained a less structured region that was not yet known. In this work, published in the Computational and Structural Biotechnology Journal, the researchers have used structure prediction tools including Alphafold, to identify a helical region aligned with the cell membrane, by the cytoplasmic part. That helix would have a positively charged region and a negatively charged region.

The solnatide, for its part, also had a region called a "dipole", with a negative and a positive charge. Thus, the researchers were able to predict that this would be the point of interaction between both structures and how they were positioned for that interaction.

Researchers from the Catalan biotech BCN Peptides in Barcelona (Spain), and from the American universities Medical College of Georgia at Augusta University and Emory University School of Medicine, in Atlanta, have also collaborated in the work.

Responsible

Participants

Roberto García Ruiz

Catedrático UJA

Antonio Molina Díaz

Catedrático UJA

Juan Gómez Ortega

Catedrático UJA

Scroll to Top

Intranet access

The party responsible for processing the personal data included in this form is the University of Jaén, Campus Las Lagunillas s/n. 23071 Jaen, dpo@ujaen.es. The data will be processed by the University of Jaén as data controller, for the purpose of the request made through this contact form.

The legitimacy for the treatment is given by the fulfillment of a legal obligation and mission and public power (Organic Law 2/2023, of March 22 of the University System), and in the consent expressed by sending this form.

The data will not be transferred to third parties, except when legally appropriate.

The entity uses the services provided by Google, so international data transfers can be made. These international data transfers are based on standard contractual clauses determined in accordance with the General Data Protection Regulation by the European Commission.

You may exercise the rights of access, rectification, opposition, deletion, limitation of treatment, portability and not being subject to individualized decisions. To exercise these rights, you must send a communication either by written request to the aforementioned address or through the email dpo@ujaen.es, specifying which of these rights you request to be satisfied.

You should know that, when the University has reasonable doubts about the applicant’s identity, they may be required to provide the necessary identification documentation to confirm their identity. In the event that he acts through a representative, legal or voluntary, he must also provide a document proving the representation and identification document of the same.

In the event that you consider that your rights have not been duly addressed, you can file a claim with the Andalusian Council for Transparency and Data Protection. www.ctpdandalucia.es or before the Data Protection Delegate of the University of Jaén (dpo@ujaen.es).

Acceso a Intranet

El responsable del tratamiento de los datos personales incluidos en el presente formulario es la Universidad de Jaén, Campus Las Lagunillas s/n. 23071 Jaén, dpo@ujaen.es. Los datos serán tratados por la Universidad de Jaén en calidad de responsable del tratamiento, con el fin de la solicitud planteada a través de este formulario de contacto.

La legitimación para el tratamiento viene dada por el cumplimiento de una obligación legal y misión y poder público (Ley Orgánica 2/2023, de 22 de marzo del Sistema Universitario), y en el consentimiento manifestado mediante la remisión del presente formulario.

Los datos no serán cedidos a terceros, salvo cuando legalmente proceda.

La entidad utiliza los servicios prestados por Google, por lo que pueden efectuarse transferencias internacionales de datos. Estas transferencias internacionales de datos se basan en las cláusulas contractuales tipo determinadas conforme al Reglamento General de Protección de Datos por la Comisión Europea.

Ud. podrá ejercitar los derechos de acceso, rectificación, oposición, supresión, limitación del tratamiento, portabilidad y de no ser objeto de decisiones individualizadas. Para ejercitar dichos derechos deberá enviar comunicación bien mediante solicitud escrita a la dirección anteriormente citada o bien a través del correo electrónico dpo@ujaen.es, especificando cuál/es de estos derechos solicita sea satisfecho.

Debe saber que, cuando la Universidad tenga dudas razonables sobre la identidad del solicitante, se le podrá requerir que facilite la documentación identificativa necesaria para confirmar su identidad. En caso de que actuara mediante representante, legal o voluntario, deberá aportar también documento que acredite la representación y documento identificativo del mismo.

En el supuesto que usted considere que sus derechos no han sido debidamente atendidos, puede presentar una reclamación ante el Consejo de Transparencia y Protección de Datos de Andalucía. www.ctpdandalucia.es o ante el Delegado de Protección de Datos de la Universidad de Jaén (dpo@ujaen.es).